EML4 –ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib
We report anEML4 –ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests thatEML4 –ALK genomic testing may be clinically useful in patients with heavy smoking history.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Skin Cancer | Smokers | Squamous Cell Carcinoma | Translocation